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OBJECTIVE — To implement and evaluate a regional prepregnancy care program in women
with type 1 and type 2 diabetes.
RESEARCH DESIGN AND METHODS — Prepregnancy care was promoted among
patientsandhealthprofessionalsanddeliveredacross10regionalmaternityunits.Aprospective
cohort study of 680 pregnancies in women with type 1 and type 2 diabetes was performed.
Primary outcomes were adverse pregnancy outcome (congenital malformation, stillbirth, or
neonatal death), congenital malformation, and indicators of pregnancy preparation (5 mg folic
acid, gestational age, and A1C). Comparisons were made with a historical cohort (n  613
pregnancies) from the same units during 1999–2004.
RESULTS — A total of 181 (27%) women attended, and 499 women (73%) did not attend
prepregnancycare.Womenwithprepregnancycarepresentedearlier(6.7vs.7.7weeks;P0.001),
were more likely to take 5 mg preconception folic acid (88.2 vs. 26.7%; P0.0001) and had lower
A1C levels (A1C 6.9 vs. 7.6%; P  0.0001). They had fewer adverse pregnancy outcomes (1.3 vs.
7.8%;P0.009).Multivariatelogisticregressionconﬁrmedthatinadditiontoglycemiccontrol,lack
of prepregnancy care was independently associated with adverse outcome (odds ratio 0.2 [95% CI
0.05–0.89]; P0.03). Compared with 1999–2004, folic acid supplementation increased (40.7 vs.
32.5%; P  0.006) and congenital malformations decreased (4.3 vs. 7.3%; P  0.04).
CONCLUSIONS — Regional prepregnancy care was associated with improved pregnancy
preparation and reduced risk of adverse pregnancy outcome in type 1 and type 2 diabetes.
Prepregnancy care had beneﬁts beyond improved glycemic control and was a stronger predictor
of pregnancy outcome than maternal obesity, ethnicity, or social disadvantage.
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R
ates of adverse pregnancy outcome
(congenital malformation, still-
birth, or neonatal death) in women
with diabetes are three to ﬁve times
greater than those of the background ma-
ternity population (1,2). It is therefore
recommended that all women of repro-
ductive age with diabetes are offered an-
nualpreconceptioncounselingandadvised
toavoidunplannedpregnancy(3).Prepreg-
nancy care is the targeted support and ad-
ditional clinical care offered to women
planning pregnancy.
It is well established that for women
with type 1 diabetes, specialist prepreg-
nancy care improves glycemic control
and reduces adverse pregnancy outcomes
(4–11). Yet, despite documented beneﬁts
in selected centers of excellence, only two
regional programs have been described,
both almost 20 years ago (4,11). Failure
to improve prepregnancy care provision
leaves a majority of women at increased
risk of potentially preventable poor preg-
nancyoutcomes.Thiswasconﬁrmedbythe
Conﬁdential Enquiry for Maternal and
Child Health, revealing that only 17% of
U.K. maternity units offer prepregnancy
care and that only 10% of women, mostly
those with type 1 diabetes, attend (12).
Type2diabeteshasnowemergedasa
growing concern in pregnancy (13).
Women with type 2 diabetes are predom-
inantly cared for in community settings
and are unlikely to access specialist
prepregnancy care. Studies (12,14–16)
from the U.K., France, and Denmark
demonstrate a clear association between
poor pregnancy preparation and adverse
pregnancy outcomes in type 2 diabetes.
Women with type 2 diabetes also tend to
be older, more obese, more ethnically di-
verse, more socially disadvantaged, and
more likely to have concomitant comor-
bidities,factorsthatareallassociatedwith
poor pregnancy outcome (12).
The additional health inequalities, obe-
sity, and obstetric risk factors of women
withtype2diabetesarenoteasilyovercome
by prepregnancy care. However, women
with type 2 diabetes are more likely to take
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achieve stricter glycemic control. Hence,
prepregnancy care may be even more effec-
tive for women with type 2 diabetes than
women with type 1 diabetes.
The aim of this study was to evaluate
the effectiveness of a regional prepregnancy
care program on pregnancy preparation,
glycemic control, and pregnancy outcomes
in women with type 1 and type 2 diabetes.
RESEARCH DESIGN AND
METHODS— We documented the
potentially modiﬁable risk factors for ad-
verse pregnancy outcomes in type 1 and
type 2 diabetes (14) and established an
interdisciplinary regional prepregnancy
care team. We also performed a qualita-
tive study to identify women’s barriers to
accessing prepregnancy care, namely be-
liefs that strict glycemic targets were un-
realistic, poor relationships with health
professionals, and desire for a less-
medicalized pregnancy (17).
Prepregnancy care promotion
A theoretically guided preconception
leaﬂet (the East Anglican Study for Improv-
ingPregnancyOutcomesinWomenwithDi-
abetes[EASIPOD]leaﬂet)withadviceand
telephone contacts for a prepregnancy
care coordinator was mailed annually to
all women aged 16–45 years identiﬁed
from specialist and primary-care diabetes
registers. We targeted health profession-
als including nurses, general practitio-
ners, retinal-screening teams, health
visitors, midwives, community pharma-
cists, and disseminated information via
pharmacist medicine use reviews, struc-
tured education programs, local en-
hanced service agreements, and patient
support groups.
Prepregnancy and antenatal care
delivery
Prior to pregnancy, women with type 2
diabetes were predominantly cared for by
primary-care teams in community set-
tings and women with type 1 diabetes by
specialistteamsinhospitalsettings.Refer-
rals were accepted from specialist provid-
ers, primary care, and directly from
women who received the EASIPOD leaf-
let. Prepregnancy care was delivered in
specialist clinics without additional fund-
ing using a standardized proforma (see
the online appendix, available at http://
care.diabetesjournals.org/cgi/content/full/
dc10-1113/DC1). The content was stan-
dardizedthroughoutthestudyperiod(10
January 2006 through 31 September
2009) but delivered by different health
care providers (diabetes physician, spe-
cialist nurse, midwife, or obstetrician).
Joint clinics with diabetes and obstetric
inputwereheldinthreelargerunits(30
deliveriesperyear),whereassmallerunits
provided appointments with individual
nurses or physicians. The same specialist
multidisciplinary health care teams pro-
vided antenatal care to women with type
1 and type 2 diabetes during pregnancy.
Data collection
Pregnancies were registered as soon as
contactwiththeantenatalteamwasestab-
lished. A data collection proforma was
completed for all registered pregnancies
within 3 months of pregnancy comple-
tion. The project coordinator facilitated
timely data collection, validation of data,
and entry onto a study database.
Maternal data
Pregnancies were described as planned if
contraception was discontinued for the
purposes of pregnancy. All other pregnan-
cies were unplanned. Preconception coun-
seling was documentary evidence of a
discussion regarding the pregnancy risks
associatedwithdiabetes.Prepregnancycare
was deﬁned as a woman working in part-
nership with health professionals to opti-
mize pregnancy outcome and required
documented attendance at a prepregnancy
clinic.
Quintiles of deprivation were derived
from the postcode of residence according
to the East of England Index of Multiple
Deprivations(IMD)scores.MaternalA1C
levels were recorded up to 6 months pre-
conception and at up to 4–8 weekly in-
tervals during pregnancy. They were
assayedusingDiabetesControlandCom-
plications Trial–aligned methodology
(normal reference range 3.6–5.8%) in ac-
creditedlaboratories,withallcenterspar-
ticipating in the national external quality-
assurance program.
Pregnancy outcome measures
Miscarriage was deﬁned as the spontane-
ousendingofpregnancybefore24weeks.
We recorded termination of pregnancy
for fetal malformation and described all
other terminations as nontherapeutic.
Congenital malformations were con-
ﬁrmed by postmortem results, genetic
ﬁndings, or correspondence and classi-
ﬁed according to the European Surveil-
lance of Congenital Anomalies system.
Stillbirth was fetal death after 24 weeks
and neonatal death as death of a live-born
infant before 28 days. A serious adverse
outcome was one that resulted in major
congenitalmalformation(includedtermi-
nation), stillbirth, or neonatal death.





for continuous variables. For multivariate
analyses,logisticregressionwasused.The
major hypothesis of interest was whether
prepregnancy care was effective in reduc-
ing adverse pregnancy outcomes, inde-
pendent of potential confounding
variables. Therefore, the model included
maternal age, type of diabetes, diabetes
duration, A1C at booking, ethnicity, so-
cioeconomic status, BMI, parity, and
smoking history as predictors in addition
to whether women received prepreg-
nancy care.
The annual birth rate for the 10 cen-
tersinthestudyis50,000,ofwhich200
births are complicated by pregestational
diabetes. We calculated that a sample size
of 580 pregnancies would give 80%
power to detect a 30% reduction in the
rate of serious adverse outcomes assum-
ing 50% prepregnancy care uptake and
10% adverse outcomes.
RESULTS— During the 3-year study
period, 686 pregnancies (median 77 per
center [range 25–111]) were registered.
Six pregnancies in women who moved
intotheregionduringpregnancywereex-
cluded. For the remaining 680 pregnan-
cies, there were no differences in the
pregnancy-planning intentions (50%
planned) of women with type 1 and type
2 diabetes. Women with type 1 diabetes
were more likely to have preconception
counseling (54 vs. 32%; P  0.0001).
Overall, 181 (27%) women attended
prepregnancy care, with signiﬁcantly
more attendees having type 1 compared
with type 2 diabetes (31 vs. 20%; P 
0.0009). The median number of prepreg-
nancy care visits was three (range, one to
seven). Among 499 (73%) women with-
out prepregnancy care, 157 (32%) had
documented preconception counseling.
Maternal characteristics
Women who attended prepregnancy care
were more likely to be white and less
likely to live in a deprived area, smoke
cigarettes, and to be overweight or obese
(Table 1). However, almost half of the
women who attended prepregnancy care
Murphy and Associates
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4–5).
Pregnancy preparation
Attendees were more likely to have had
preconception counseling (P  0.0001)
and to have read the EASIPOD leaﬂet
(P  0.0001). They were more likely to
have5mgpreconceptionfolicacid(88vs.
27%; P  0.0001) and less likely to con-
ceive on potentially harmful ACE inhibi-
tors (1.1 vs. 4.6%; P  0.05) and/or
statins (0 vs. 7.6%; P  0.0003). How-
ever, 10% of pregnancies occurred earlier
than expected, some before folic acid
(12%) was started or ACE inhibitors were
stopped (1%).
Attendees presented earlier for ante-
natalcare(P0.0001),with70%having
their ﬁrst antenatal contact before 8
weeks. Their glycemic control was signif-
icantlybetterbeforepregnancyandatﬁrst
contact (P  0.0001), although only 53%
achieved A1C 7%, and even fewer
(17.8%) (10.9% type 1 diabetes, 32%
type 2 diabetes) achieved the National In-
stitute for Health and Clinical Excellence
(NICE) glycemic control target A1C
6.1%.
Pregnancy outcomes
Detailed pregnancy outcomes are avail-
able for 676 pregnancies (665 singleton
and 11 twin), excluding four pregnancies
inwomenwhomovedoutofthearea(Ta-
ble 2). There were 2 adverse outcomes
(one malformation and one stillbirth) in
women with prepregnancy care and 32
adverse outcomes (23 malformations, six
stillbirths, and three neonatal deaths) in
women without prepregnancy care (1.3
vs. 7.8%; P  0.009). Gestational age at
delivery and neonatal morbidity were
comparable, with equal rates of preterm
delivery (50 of 150 vs. 116 of 397; P 
0.4), large-for-gestational-age babies (70
of 145 vs. 170 of 372; P  0.7), and neo-
natal care admissions (50 of 147 vs. 152
of 386; P  0.5) in women who did and
did not attend.
Effects of prepregnancy care in type
2 compared with type 1 diabetes
For women with type 1 diabetes, there
were no differences in ethnicity or socio-
economicstatusofwomenwithandwith-
out prepregnancy care (supplementary
Table).Aspertheentirecohort,attendees
had improved glycemic control and their
offspringhadreducedriskofadverseout-
come (1.9 vs. 8.8%; P  0.03).
Inwomenwithtype2diabetes,atten-
Table 1—Characteristics of pregnancies in women with type 1 and type 2 diabetes according
to prepregnancy care attendance
PPC No PPC P value
Demographic data* n  181 n  499
Age (years)
Median (10th–90th centile) 33 (26–39) 31 (22–39) 0.002
Ethnicity
White 166 (91.7) 387 (77.6) 0.0005
Asian 12 (6.6) 90 (18.0)
Other 3 (1.7) 22 (4.4)
Social deprivation n  177 n  496
Quintile 1 (least deprived) 30 (16.9) 65 (13.1) 0.01
Quintile 2 27 (15.3) 67 (13.5)
Quintile 3 47 (26.6) 91 (18.3)
Quintile 4 34 (19.2) 100 (20.2)
Quintile 5 (most deprived) 39 (22.0) 173 (34.9)
Weight n  176 n  451
Weight at booking (kg)
Median (10th–90th centile) 71.5 (56.9–99.0) 74.5 (58.0–105.0) 0.03
BMI at booking (kg/m
2)
Median (10th–90th centile) 26.1 (21.3–36.2) 27.9 (22.2–38.1) 0.005
Normal (BMI 24.9) 73 (41.5) 131 (29.0)
Overweight (BMI 25–29.9) 45 (25.6) 147 (32.6)
Obese (BMI 30) 58 (33.0) 173 (38.4)
Diabetes status n  181 n  499
Diabetes duration (years)
Median (10th–90th centile) 10 (2–27) 7 (1–22) 0.01
Maternal complications
Retinopathy 43 (23.8) 91 (18.2) 0.1
Nephropathy 5 (2.8) 11 (2.2) 0.9
Neuropathy 3 (1.7) 10 (2.0) 1.0
Glycaemic control
A1C prepregnancy (%)
Median (10th–90th centile) 7.2 (6.0–8.8) 8.1 (6.1–11.7) 0.0001
A1C at ﬁrst contact (%)
Median (10th–90th centile) 6.9 (5.8–8.8) 7.6 (6.0–10.1) 0.0001
A1C 7.0%† 72/135 (53.3) 113/298 (37.9) 0.004
A1C ﬁrst trimester (%)
Median (10th–90th centile) 6.9 (5.8–8.4) 7.4 (6.0–9.7) 0.0001
A1C second trimester (%)
Median (10th–90th centile) 6.4 (5.4–7.4) 6.5 (5.5–8.2) 0.001
A1C third trimester (%)
Median (10th–90th centile) 6.4 (5.5–7.5) 6.5 (5.3–7.9) 0.05
Diabetes treatment at conception
Diet alone 4 (2.2) 69 (13.8) 0.0001
Insulin 166 (91.7) 317 (63.5) 0.0001
Sulphonylurea 0 (0) 16 (3.2) 0.03
Metformin 40 (22.1) 124 (24.8) 0.5
Metformin alone 12 107
Metformin and insulin 28 17
Glitazone 1 (0.6) 21 (4.2) 0.03
Diabetes therapy at delivery
Insulin 154/154 (100) 384/408 (94.1) 0.004
Pregnancy preparation
Preconception counselling 150/181 (82.9) 157/496 (31.7) 0.0001
EASIPOD leaﬂet read 68/156 (43.6) 67/451 (14.9) 0.0001
Planned pregnancy 162/178 (91) 168/448 (37.5) 0.0001
Folic acid preconception 157/178 (88.2) 112/420 (26.7) 0.0001
Potentially harmful medications
ACE inhibitor at conception 2 (1.1) 23 (4.6) 0.05
Statin therapy at conception 0 (0) 38 (7.6) 0.0003
Gestational age at booking (weeks)
Median (10th–90th centile) 6.7 (4.4–10.2) 7.7 (5.1–14.6) 0.0001
continued
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their better glycemic control (compared
with women with type 1 diabetes),
prepregnancy care attendees still
achieved signiﬁcantly better glycemic
control both before pregnancy (P 
0.0001) and throughout the ﬁrst two tri-
mesters (P  0.007 and P  0.03). There
were no malformations or adverse out-
comes in the offspring of attendees com-
pared with 10 malformations (5.6%) and
12 adverse outcomes (6.8%) in the off-
spring of women without prepregnancy
care, but with small numbers these differ-
ences were not signiﬁcant.
Predictors of serious adverse
pregnancy outcome
In contrast to the general maternity pop-
ulation,maternalage,parity,obesity,eth-
nicity, and socioeconomic deprivation
were not independently associated with
adverse outcome (Table 3). The indepen-
dent predictors were glycemic control at
booking (odds ratio 1.46 [95% CI 1.16–
1.85]; P  0.001 per 1% A1C increase)
andlackofprepregnancycare(0.2[0.05–
0.89]; P  0.03). Diabetes duration and
type 1 diabetes approached, but did not
reach,signiﬁcance(P0.06andP0.07).
Pregnancy outcomes during 2006–
2009 compared with during
1999–2004
Notable differences were the increased
proportion of pregnancies complicated
by type 2 diabetes (40 vs. 27%; P 
0.0001), increased preconception coun-
selingandfolicacidsupplementationpar-
ticularly in type 1 diabetes, and increased
metformin use in type 2 diabetes (Table
4). Despite fewer malformations (4.3 vs.
7.3%;P0.04)duringtheprepregnancy
care program, overall differences in peri-
natal mortality (1.8 vs. 3.7%; P  0.07)
and adverse outcome (6.0 vs. 9.2%; P 
0.07) were not signiﬁcant. Rates of ad-
verse outcomes were unchanged (6.5%)
in type 1 diabetes. In type 2 diabetes, there
were reductions both in adverse outcomes
(5.3 vs. 16.4%; P0.0008) and in malfor-
mations (4.5 vs. 12.3%; P  0.009).
CONCLUSIONS — Here, we report
the development and evaluation of a re-
gional prepregnancy care program, im-
plemented in routine care, which was
associated with improved glycemic con-
trol and reduced risk of adverse preg-
nancy outcome in pregnancies
complicated by both type 1 and type 2
diabetes. Approximately half the women
Table 1—Continued
PPC No PPC P value
Booked before 8/40 117/167 (70.0) 240/457 (52.5) 0.0001
Smoking status at conception
Nonsmoker 151 (83.9) 348 (71.4) 0.0002
Ex-smoker 15 (8.3) 34 (7.0)
Current smoker 14 (7.8) 105 (21.6)
Data are n (%) unless otherwise indicated. *Six pregnancies in women who moved into the area during
pregnancy are excluded as details of their preconception counseling and prepregnancy care were lacking.
†The proportion of women achieving the more stringent NICE-recommended A1C target of 6.1% intro-
duced during this study was 17.8% women with prepregnancy care (10.9% type 1 diabetes, 32% type 2
diabetes) vs. 10.4% (5.1% type 1 diabetes, 16.5% type 2 diabetes) without prepregnancy care (P  0.05).
Table2—Pregnancyoutcomesofwomenwithdiabetesaccordingtoprepregnancycareattendance
PPC No PPC P value
Pregnancy outcome
1 n  181 n  495
Miscarriage 28 (15.5) 71 (14.3) 0.9
Termination of pregnancy 1 25
Termination of pregnancy fetal
abnormality 0 9 0.2
Termination of pregnancy non-
diabetes associated* 11 6
Delivery
2 n  152 n  399
Gestational age at delivery (weeks)
Median (10th–90th centile) 37.6 (34.6–38.9) 37.7 (34.7–39.0) 0.3
Type of delivery
SVD including instrumental 53 (34.9) 177 (44.4) 0.05
LSCS 99 (65.1) 222 (55.6)
Planned LSCS 49 (32.2) 101 (25.3) 0.6




3 n  150 n  397
37 weeks gestation 50 (33.3) 116 (29.2) 0.4
34 weeks gestation 9 (6.0) 27 (6.8) 0.9
Infant birth weight centiles
4 n  145 n  372
Large for gestational age 70 (48.3) 170 (45.7) 0.7
Extremely large for gestational age 50 (34.4) 114 (30.6) 0.5
Small for gestational age 7 (4.8) 32 (8.6) 0.2
Neonatal care
5 n  147 n  386 0.5
Home birth 0 (0) 1 (0.3)
Postnatal ward 74 (48.3) 183 (47.4)
Level 1 23 (15.6) 50 (13.0)
Level 2 37 (25.2) 123 (31.9)
Level 3 13 (8.8) 29 (7.5)
Pregnancy outcomes
6 n  152 n  408
Malformation 1 (0.7) 23 (5.6) 0.02
Stillbirth 1 (0.7) 6 (1.5) 0.7
Neonatal death 0 (0) 3 (0.7) 0.7
Perinatal mortality 1 (0.7) 9 (2.2) 0.4
Serious adverse outcome (malformation
with or without termination of
preganancy, stillbirth, or
neonatal death) 2 (1.3) 32 (7.8) 0.009
Data are n (%) unless otherwise indicated.
1All pregnancies excluding four pregnancies in women who
moved out of the area during pregnancy (n  676). *We are conﬁdent that all pregnancy termination data
inwomenwithprepregnancycareareincludedbutcannotexcludeanevenhighernumberofnontherapeutic
terminations in women without prepregnancy care.
2All pregnancies after 20 weeks’ gestation excluding 99
spontaneous miscarriages and 26 terminations (n  551).
3All pregnancies excluding four infants for whom
data on gestational age at delivery were missing (n  547).
4All pregnancies resulting in live singleton births
excluding 18 for whom birth weight centiles were missing (n  517).
5All pregnancies resulting in live
singleton births excluding one infant in whom care level was not recorded (n  533).
6All pregnancies after
20 weeks’ gestation (551) and 9 terminations for congenital malformation (n  560).
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mented preconception counseling, sug-
gesting fairly widespread health care
interaction. However, less than a third
beneﬁted from prepregnancy care, sug-
gesting failings of conventional models of
engagement. This emphasizes the need to
rethink how preconception counseling is
deliveredbothatapopulationlevelandto
women with preexisting medical condi-
tions. In the U.K., preconception services
are fragmented and variable, comparing
poorly to other European countries,
where effective prepregnancy care has
been successfully implemented (2).
In contrast to other U.K. and U.S.
studies, we found no association between
social disadvantage and prepregnancy
care attendance in women with type 1 di-
abetes (18,19). Ethnicity and living in a
deprived area were barriers to access only
inwomenwithtype2diabetes.Ourqual-
itative study suggested that unrealistic
glycemic control targets, poor communi-
cation,and“toomuchemphasisonallthe
bad things that could happen” are impor-
tant barriers to engagement both for
women with type 1 and type 2 diabetes
(17), further emphasizing the need to de-
liver prepregnancy care in a positive, mo-
tivating, and supportive manner.
Inthiscohort,neitherage,parity,eth-
nicity, social disadvantage, nor obesity
predicted adverse pregnancy outcome.
This could be because the study was un-
derpowered to examine these effects or
because glycemic control and pregnancy
preparationarethestrongestinﬂuencesof
adverse outcome in pregnancies compli-
cated by type 1 and type 2 diabetes.
Challenges in type 1 diabetes
Even motivated attendees struggled to
achieve optimal preconception glycemic
control. Among women with type 1 dia-
betes, only 10% with prepregnancy care
and 5% without prepregnancy care
achieved A1C levels 6.1% compared
Table 3—Independent predictors of serious adverse pregnancy outcome (major congenital
malformation, stillbirth, or neonatal death) in pregnancies complicated by type 1 and type 2
diabetes
Variable Odds ratio (95% CI) P value
Age (years)
1 1.01 (0.93–1.09) 0.9
Type 1 diabetes
2 3.41 (0.89–13.0) 0.07
Duration of diabetes (years)
3 1.06 (1.00–1.12) 0.06
A1C at booking
4 1.46 (1.16–1.85) 0.001
European ethnicity 0.36 (0.09–1.46) 0.2
Social disadvantage 1.00 (0.76–1.32) 1.0
Prepregnancy care
5 0.20 (0.05–0.89) 0.03
BMI 0.95 (0.88–1.03) 0.2
Parity
6 1.77 (0.75–4.14) 0.2
Smoking 1.41 (0.93–2.15) 0.1
1Increase in risk for every extra year of age.





5Decrease in risk for women who attend a prepregnancy care clinic as compared with women who
did not attend prepregnancy care.




1999–2004 2006–2009 P value
Type of diabetes
1
Type 1 443 408 0.0001
Type 2 162 (26.8) 274 (40.2)
Pregnancy loss 20/40 60/613 (9.8) 125/686 (18.5) 0.0001
Preconception counselling
2 200/535 (32.5) 245/562 (43.6) 0.04
Type 1 diabetes 153/389 (40.5) 178/337 (52.8)
Type 2 diabetes 42/146 (28.7) 67/225 (29.8)
Folic acid preconception 174/535 (32.5) 229/562 (40.7) 0.006
Type 1 diabetes 142/389 (36.4) 155/337 (46.0)
Type 2 diabetes 32/146 (21.9) 74/225 (32.9)
Metformin
Type 2 diabetes 51/146 (35.2) 123/225 (54.7) 0.0003
Pregnancy outcome
2
Congenital malformation 39/535 (7.3) 24/562 (4.3) 0.04
Type 1 17/389 (4.4) 14/337 (4.2) 1.0 (P  0.05 for interaction)
Type 2 18/146 (12.3) 10/225 (4.4) 0.009
Perinatal mortality 20/535 (3.7) 10/562 (1.8) 0.07
Type 1 11/389 (2.8) 8/337 (2.4) 0.9 (P  0.03 for interaction)
Type 2 9/146 (6.2) 2/225 (0.9) 0.009
Serious adverse outcome 49/535 (9.2) 34/562 (6.0) 0.07
Type 1 25/389 (6.4) 22/337 (6.5) 0.9 (P  0.007 interaction)




with the 1999–2004 study, we have excluded all pregnancies that resulted in miscarriage at 20 weeks’ gestation and all terminations for indications other than
congenital malformation.
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women with type 2 diabetes. It should be
noted that only a minority of women
(9.4%) used insulin pump therapy before
or during pregnancy and that continuous
glucose monitoring was not routinely
available. Consequently, despite im-
proved pregnancy preparation in women
with type 1 diabetes, their glycemic con-
trol and risk of adverse pregnancy out-
come were disappointingly unchanged
over the two study periods. A nationwide
Swedish study of over 5,000 pregnancies
also concluded that type 1 diabetes is still
associated with considerably increased
adverse obstetric and perinatal outcomes,
again highlighting a lack of progress over
the past decade (20).
There is emerging evidence support-
ing the beneﬁts of continuous glucose
monitoring both before and during preg-
nancy (21,22). Large multicenter studies
arenowneededtoevaluatetheeffectsand
cost effectiveness of continuous glucose
monitoring on maternal glycemic control
and pregnancy outcomes. Recent innova-
tions, including sensor-augmented insu-
lin pumps and closed-loop technologies,
may also help more women with type 1
diabetes to achieve near normoglycaemia
(23,24).
Improvements in type 2 diabetes
This study has highlighted encouraging
improvements for pregnant women with
type 2 diabetes, with signiﬁcant reduc-
tions in rates of adverse pregnancy out-
comes, over the past decade. This may
represent a milder glycemic disturbance
(25)and/orimprovementsinthemanage-
ment of type 2 diabetes. Importantly, it
suggests that organized efforts to improve
preconception glycemic control can have
a beneﬁcial effect for women with type 2
diabetes despite their obstetric risk
factors.
Strengths and limitations
We carefully documented the maternal
demographics and obstetric and diabetes
risk factors in a large, contemporary co-
hort of women with diabetes. The pro-
gramwasimplementedacross10regional
maternity units, reducing selection bias
from specialist centers of excellence. A
major strength is the inclusion of women
with both type 1 and type 2 diabetes and
the detailed content and delivery format
for prepregnancy care, which previous
studies lack. Furthermore, we evaluated
the role of prepregnancy care in addition
to preconception counseling and in-
cluded details of preconception medica-
tion use and of pregnancy terminations,
documenting the prevalence of termina-
tions(boththerapeuticandnontherapeu-
tic) in women with diabetes.
A limitation is that it is not a random-
ized trial, and differences in the motiva-
tion of women who do and do not attend
prepregnancy care are likely. However, a
randomized trial is neither ethical nor
clinically feasible. We therefore per-
formed a robust observational cohort
study, documenting and correcting for
potential confounding factors, including
age, parity, obesity, ethnicity, and socio-
economicstatus.Wealsohaveahistorical
cohort with details of pregnancy out-
comesinthesamecentersbeforeanddur-
ing the program (14).
Prepregnancy care has failed to keep
pace with recent educational and techno-
logical developments. Structured pro-
grams with evidence-based curriculums,
standardized delivery by trained health
professionals, and access to continuous
glucose monitoring and insulin pump
therapy are urgently required. For
women with diabetes, prepregnancy care
is as essential as antenatal care and needs
to be resourced, quality assured, and re-
searchedtoasimilarstandard.Morework
is needed to increase attendance, over-
come the socioeconomic and ethnic bar-
riers to access in type 2 diabetes, and to
further improve glycemic control in type
1 diabetes.
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